Therapeutic effects of low-dose,ultra-low-dose and standard-dose chemotherapy for elderly acute myeloid leukemia
10.3760/cma.j.issn.1009-9921.2009.12.006
- VernacularTitle:小剂量、超小剂量及标准剂量化疗治疗老年人急性髓系白血病的疗效研究
- Author:
Jihao ZHOU
;
Wei ZHAO
;
Jijun WANG
;
Hongmei JING
;
Yan LIU
;
Yuping CHEN
;
Xiaoyan KE
- Publication Type:Journal Article
- Keywords:
Leukemia;
myeloid;
acute;
Aged;
Drug therapy;
combination
- From:
Journal of Leukemia & Lymphoma
2009;18(12):725-728
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic effect of low-dose,ultra-low-dose and standard dose chemotherapy for elderly acute myeloid leukemia.Methods A retrospective analysis was performed on 77 elderly AML patients aged 60 years or older.The short-term and long-term effects were compared among low-dose,uhtra-low-dose and standard-dose chemotherapy.Results Although patients receiving low-dose or ultra-low-dose chemotherapy were older,with higher PS scores and lower WBC count,there were no significant differences in CR rate,ORR,EFS or OS between patients who received low-dose/ultra-low-dose chemotherapy and standard-dose chemotherapy.By dividing the total samples into subgroups according to age or PS scores,we found out that patients younger than 70 or with a PS score less than 2 showed a much better prognosis,no matter short-term or long-term,in low-dose／ultra-low-dose group rather than in the standard dose group.While in those patients older than 70 or with a PS score more than 2,the differences between those two groups were not significant.Further analysis showed that low-dose chemotherapy did not reduce treatment related mortality,neither did it increase the risk of long-term relapse.Conclusion Low-dose and ultra-low-dose chemotherapy can improve the prognosis of elder AML patients compared with standard-dose chemotherapy,especially for elderly patients who have a better general state.
